Fludarabine
Thalassemia
Memorial Sloan Kettering Cancer CenterSmall moleculePhase 2/3Active
BB
70/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 60/ 100
- Competitive Position
- 89/ 100
Competitive context
21 Active assets in the Thalassemia cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Deferasirox Novartis Pharmaceuticals | Phase 4 | BBB |
Hydroxyurea Riphah International University | Phase 4 | BB |
ZINC SULFATE Fakultas Kedokteran Universitas Indonesia | Phase 4 | BB |
Busulphan University of California, San Francisco | Phase 2/3 | BB |
Ppsv23 Fakultas Kedokteran Universitas Indonesia | Phase 4 | BB |
View all 50 →
Same molecule, other indications
Fludarabine is also rated in:
acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)Dormant
BBB
Indicative ·
76 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →